Facebook
Twitter
LinkedIn
ForwardThe Hidden Side of Multiple Sclerosis: Harnessing Key Pathologies to Improve Outcomes Across the Multiple Sclerosis Spectrum
Program Description
The understanding of MS pathophysiology has rapidly advanced in recent years. Not only does this immense progress bring clarity to once poorly understood processes such as the drivers of progressive disease, but it has also prompted reevaluation of concepts that were once considered understood. It is now recognized that the hallmark insidious worsening of progressive disease and related pathologies are not limited to classically progressive phenotypes. In fact, these features often begin early in relapsing disease.
Fortunately, literature is beginning to home in on strategies for better capturing and monitoring subclinical disease changes as well as how, if at all, they may be affected by available therapeutics. This has been of particular interest as novel strategies such as Bruton tyrosine kinase inhibitors (BTKi’s) have shown promise in potentially reaching these largely neglected contributors to MS progression due to their unique actions both peripherally and centrally. However, with the first phase 3 results from a BTKi recently failing to meet their primary endpoints, it is critical to discuss the implications of these findings and whether they may apply others in this agent class that are still undergoing investigation. Further, these results also raise key questions about the evolution and optimization of MS management as a whole.
Target Audience
The target audience for this CME initiative includes neurodegenerative disease specialists, general neurologists, advanced practice neurology professionals, registered nurses, and other healthcare professionals involved in the diagnosis and long-term management of patients with MS.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Describe early peripherally-initiated (e.g., gadolinium enhancing lesions) and central (e.g., slowly expanding lesions [SELs]) MS pathologies to raise early suspicion of MS and improve prognostication
- Employ modern disease frameworks (e.g., progression independent of relapses [PIRA]) and assessment strategies (e.g., timed 25-foot walk [T25FW], nine-hole peg test [9-HPT]) to differentiate types/implications of disease worsening and monitor patients for each
- Assess the impact of available disease-modifying therapies (DMTs) on early MS pathologies to determine for which patients these may be optimal strategies
- Evaluate the mechanisms of action, clinical profiles, and phase 2/3 data with BTKi’s in MS to determine their utility in potential future management
Jiwon Oh, MD, PhD, FRCPC, FAAN
Medical Director, Barlo MS Program, St. Michael’s
Hospital, Scientist, Keenan Research Centre Li Ka
Shing Knowledge Institute, Associate Professor of
Medicine, University of Toronto, Canada
Stephen Krieger, MD, FAAN
Professor of Neurology
Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY
Darin Okuda, MD
Professor of Neurology
Director, Neuroinnovation Program
Director, Multiple Sclerosis & Neuroimmunology Imaging Program
UT Southwestern Medical Center
Dallas, TX
This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC. In conjunction with the 2024 Annual Meeting of the CMSC.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statement
Disclosure of Relevant Financial Relationships
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in an accredited continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality accredited continuing education activities that promote improvements or quality in health care and not the business interest of an ineligible company.
Staff Disclosures
Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Sanofi. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Commercial Support
This activity is supported by educational grant from Sanofi.
Method of Participation
There are no fees for participating in and receiving credit for this activity. During the event, participants must: 1) read the learning objectives and faculty disclosures; 2) complete the pre-activity assessment; 3) participate in the live activity; and 4) complete the post-assessment and evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form.
Media
Live
This symposium is neither sponsored nor endorsed by the Consortium of Multiple Sclerosis Centers.